Clinical Trial Detail

NCT ID NCT02287727
Title Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements no
Sponsors Roswell Park Cancer Institute
Indications

rectum adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.